TARGET AUDIENCE: Medical oncologists

GLOBAL LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

• Critically evaluate the available clinical trial data on the monoclonal antibody bevacizumab in breast cancer treatment, and incorporate these data into management in the metastatic setting.
• Describe the results of the recently reported adjuvant trastuzumab trials, and counsel
  appropriately selected patients about the risks and benefits of trastuzumab in the adjuvant
  setting.
• Describe the ongoing and future clinical trials evaluating monoclonal antibody therapies in
  breast cancer and counsel appropriately selected patients about participation in these studies.

CME EVALUATION: An evaluation form will be given to each participant at the conclusion of this activity.

ACCREDITATION STATEMENT: Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT: Research To Practice designates this educational activity for a maximum of 2.5 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

DISCLOSURE POLICY: As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.

EDUCATIONAL SUPPORT: This event is supported by education grants from Genentech BioOncology.